RxDoctor Payments DataLook up a doctor →

Luisa Rojas, MD

Neuromuscular Medicine · Amherst, NYNPI 1326247594

Payments from drug & device makers

$246,095in general payments, 2019–2025

Across 838 payments — averaging $293.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurology Practice Consortium GPO, LLC$172K
  • Argenx US, Inc.$58K
  • UCB, Inc.$2K
  • Tanabe Pharma America, Inc.$2K
  • MDD US Operations, LLC$1K
  • AstraZeneca$761
  • plus $10K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurology Practice Consortium GPO, LLC7$172,178
Argenx US, Inc.27$57,664
UCB, Inc.94$1,957
Tanabe Pharma America, Inc.23$1,659
MDD US Operations, LLC45$1,364
AstraZeneca(2 entities)44$761
AbbVie(2 entities)33$751
Teva Pharmaceuticals USA, Inc.42$732
Lundbeck LLC34$526
Neurocrine Biosciences, Inc.27$461
Eisai Inc.22$413
Avanir Pharmaceuticals, Inc.17$398
Neurelis, Inc.22$397
SK Life Science, Inc.16$395
Jazz Pharmaceuticals Inc.18$393
Greenwich Biosciences, Inc.49$389
Livanova USA, Inc.21$358
Amgen(2 entities)19$328
Lilly USA, LLC17$273
Alnylam Pharmaceuticals Inc.16$268
CSL Behring7$251
Novartis16$247
GE HealthCare26$239
Acadia Pharmaceuticals Inc13$200
Pfizer11$196
Azurity Pharmaceuticals, Inc.6$196
Upsher-smith Laboratories LLC12$194
Catalyst Pharmaceuticals, Inc.7$166
Supernus Pharmaceuticals, Inc.10$164
Impel Pharmaceuticals Inc.7$160
Averitas Pharma Inc.7$138
Takeda Pharmaceuticals U.S.A., Inc.6$138
Harmony Biosciences LLC6$132
Mallinckrodt Hospital Products Inc.6$128
Octapharma USA, Inc.7$127
Adamas Pharmaceuticals, Inc.5$111
Johnson & Johnson6$110
Ipsen Biopharmaceuticals, Inc6$96
Sanofi6$89
Akcea Therapeutics, Inc.6$88
Kyowa Kirin, Inc.4$81
Banner Life Sciences, LLC4$81
Grifols USA, LLC3$77
Otsuka America Pharmaceutical, Inc.4$70
Boston Scientific2$61
Xeris Pharmaceuticals, Inc.3$60
Abbott4$59
Biogen3$57
Amneal Pharmaceuticals LLC4$56
Arbor Pharmaceuticals, Inc.3$46
E.r. Squibb & Sons, L.L.C.3$43
Axsome Therapeutics, Inc.2$37
Biohaven Pharmaceutical Holding Company Ltd.2$32
Almatica Pharma LLC2$32
Avion Pharmaceuticals2$31
Ultragenyx Pharmaceutical Inc.1$30
Collegium Pharmaceutical, Inc.2$30
ITF Therapeutics LLC1$26
ANI Pharmaceuticals, Inc.1$26
Mirum Pharmaceuticals, Inc.1$22

How this compares

$246,095 in reported general payments places this provider in the 85th percentile of 25 neuromuscular medicine providers in New York.

See all neuromuscular medicine providers in New York →

Medicare billing

Part B allowed, 2024
$798,002
Medicare patients
275
Services billed
21,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromuscular medicine in Amherst

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →